This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Multiple Sclerosis Association Of America Publishes 2014 MS Research Update

CHERRY HILL, N.J., Feb. 20, 2014 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update , available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions for future research are also presented.  

 

Multiple Sclerosis Association of America logo.

 

Included in this edition are updates on the currently approved drugs, such as the recently FDA-approved dosing option for Copaxone® and the FDA-labeling changes for Tysabri®. In addition to the exciting research aimed at relapsing forms of MS, a number of studies are now looking into the treatment of progressive forms of MS, which are highlighted in this edition of the MS Research Update for easy and quick identification. This update also features studies in areas such as stem-cell research, therapies for myelin repair and protection, biomarkers, genetic studies, and more.

Today, healthcare professionals and patients have numerous and more complex treatment options to consider. The need for patient education and awareness is crucial. This update and other MSAA resources are valuable tools for anyone looking for treatment information. Read or download the MS Research Update for free or order a printed copy at mymsaa.org.

For more information about MS and treatment options, please contact MSAA at (800) 532-7667, or visit mymsaa.org.

About MSAA

The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support. MSAA provides free programs and services, such as: a Helpline with professional consultants; award-winning publications, including MSAA's magazine, The Motivator; MSAA's nationally recognized website (at www.mymsaa.org), featuring award-winning educational videos and research updates; S.E.A.R.C.H.™ program to assist the MS community with learning about different treatment choices; a mobile phone app, My MS Manager™ (named one of the best multiple sclerosis iPhone & Android apps by Healthline.com); a resource database, My MS Resource Locator; safety and mobility equipment distribution; cooling accessories for heat-sensitive individuals; educational events held across the country; MRI funding; and more. For additional information, please visit www.mymsaa.org or call (800) 532-7667.

(Logo: http://photos.prnewswire.com/prnh/20120620/PH27981LOGO)

SOURCE Multiple Sclerosis Association of America

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs